We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Read MoreHide Full Article
Key Takeaways
Sionna plans to cut its workforce 46% to lower costs and focus on key CF programs.
SION-719 failed its key endpoint, prompting Sionna to stop developing it with Trikafta.
Sionna plans to advance SION-451 SION-2222 into a phase IIa CF study in 2027.
Shares of Sionna Therapeutics (SION - Free Report) declined nearly 17% yesterday after the company announced a major organizational restructuring. As part of the restructuring, Sionna intends to reduce its workforce by about 46% to lower operating expenses and focus its resources on its prioritized cystic fibrosis (CF) programs.
The workforce reduction is part of a broader cost-cutting effort following setbacks in the company’s pipeline. Sionna expects the restructuring and related actions to cost approximately $6.4 million. Per Sionna, the measures are expected to extend its cash runway into the second half of 2029.
Year to date, SION’s stock has plunged 83.3% against the industry’s 7.8% growth.
Image Source: Zacks Investment Research
SION-719 Setback Led to a Shift in Priorities
The restructuring follows disappointing clinical results for SION-719, one of Sionna’s key pipeline programs. In the phase IIa PreciSION CF proof-of-concept study, Sionna evaluated SION-719, a nucleotide binding domain 1 stabilizer, as an add-on to Trikafta, Vertex Pharmaceuticals’ (VRTX - Free Report) marketed CF treatment, in adults with CF who were homozygous for the F508del mutation.
The study did not meet its key endpoint as SION-719 failed to demonstrate a statistically significant reduction in sweat chloride levels, an important biomarker of CFTR function. Although SION-719 was generally well-tolerated, Sionna decided not to continue developing the candidate as an add-on treatment to Trikafta.
The company later conducted a post-hoc analysis and identified potential factors that may have affected the results, including pharmacokinetic outliers and complex interactions between SION-719 and Trikafta. After excluding three participants, the company reported a placebo-adjusted sweat chloride reduction of 8.6 mmol/L. However, this was a post-hoc analysis rather than the prespecified primary analysis, making the finding less conclusive.
SION’s Focus Shifts to Combo Treatment
Following the SION-719 setback, Sionna is concentrating its resources on its proprietary dual combination, SION-451 and SION-2222.
In a phase I study in healthy volunteers, SION-451 was evaluated in dual combination with either SION-2222 (galicaftor) or SION-109. The combinations met their safety, tolerability and pharmacokinetic objectives, including the targeted drug-exposure levels in CF participants.
Based on the overall phase I results, Sionna selected SION-451 + SION-2222 as its preferred combination for further development.
The company intends to advance this combination into the phase IIa AscenSION CF proof-of-concept study in the first quarter of 2027. This program is the key focus of Sionna’s CF development strategy.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of two cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have gained 67.5% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 14.7% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
View the Zacks #1 Rank List
Image: Bigstock
SION to Cut Workforce by Nearly Half After CF Study Failure, Stock Down
Key Takeaways
Shares of Sionna Therapeutics (SION - Free Report) declined nearly 17% yesterday after the company announced a major organizational restructuring. As part of the restructuring, Sionna intends to reduce its workforce by about 46% to lower operating expenses and focus its resources on its prioritized cystic fibrosis (CF) programs.
The workforce reduction is part of a broader cost-cutting effort following setbacks in the company’s pipeline. Sionna expects the restructuring and related actions to cost approximately $6.4 million. Per Sionna, the measures are expected to extend its cash runway into the second half of 2029.
Year to date, SION’s stock has plunged 83.3% against the industry’s 7.8% growth.
Image Source: Zacks Investment Research
SION-719 Setback Led to a Shift in Priorities
The restructuring follows disappointing clinical results for SION-719, one of Sionna’s key pipeline programs. In the phase IIa PreciSION CF proof-of-concept study, Sionna evaluated SION-719, a nucleotide binding domain 1 stabilizer, as an add-on to Trikafta, Vertex Pharmaceuticals’ (VRTX - Free Report) marketed CF treatment, in adults with CF who were homozygous for the F508del mutation.
The study did not meet its key endpoint as SION-719 failed to demonstrate a statistically significant reduction in sweat chloride levels, an important biomarker of CFTR function. Although SION-719 was generally well-tolerated, Sionna decided not to continue developing the candidate as an add-on treatment to Trikafta.
The company later conducted a post-hoc analysis and identified potential factors that may have affected the results, including pharmacokinetic outliers and complex interactions between SION-719 and Trikafta. After excluding three participants, the company reported a placebo-adjusted sweat chloride reduction of 8.6 mmol/L. However, this was a post-hoc analysis rather than the prespecified primary analysis, making the finding less conclusive.
SION’s Focus Shifts to Combo Treatment
Following the SION-719 setback, Sionna is concentrating its resources on its proprietary dual combination, SION-451 and SION-2222.
In a phase I study in healthy volunteers, SION-451 was evaluated in dual combination with either SION-2222 (galicaftor) or SION-109. The combinations met their safety, tolerability and pharmacokinetic objectives, including the targeted drug-exposure levels in CF participants.
Based on the overall phase I results, Sionna selected SION-451 + SION-2222 as its preferred combination for further development.
The company intends to advance this combination into the phase IIa AscenSION CF proof-of-concept study in the first quarter of 2027. This program is the key focus of Sionna’s CF development strategy.
SION’s Zacks Rank & Stock to Consider
Sionna currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) and AC Immune (ACIU - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Precigen’s 2026 bottom line have improved from a loss of two cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have gained 67.5% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 14.7% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.